Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) – FDA 483, Aug 8, 2023
An FDA inspection of Hybio Pharmaceutical Co., Ltd.'s Pingshan Factory, a sterile drug manufacturer, revealed significant deficiencies in aseptic processing and equipment cleaning. Observations included inadequate sterility testing, poor aseptic techniques by operators, and improper storage of tools, leading to potential microbiological contamination. Additionally, the firm lacked specific written procedures for cleaning and sanitizing critical equipment components within the aseptic processing area.
- Inspection date
- August 8, 2023
- Product type
- drugs
ID · 33e97dae-850f-44fe-ae93-7066ca281f55
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.